Maintenance of Functionality Without Flushing of Totally Implantable Venous Access Devices: A Presentation of Clinical Cases

IF 1.4 Q3 PERIPHERAL VASCULAR DISEASE
Martina Rapisarda , Luisa Gallo , Alessandro Terrasi , Ivan Lo Iacona , Isidoro Di Carlo , Adriana Toro
{"title":"Maintenance of Functionality Without Flushing of Totally Implantable Venous Access Devices: A Presentation of Clinical Cases","authors":"Martina Rapisarda ,&nbsp;Luisa Gallo ,&nbsp;Alessandro Terrasi ,&nbsp;Ivan Lo Iacona ,&nbsp;Isidoro Di Carlo ,&nbsp;Adriana Toro","doi":"10.1016/j.ejvsvf.2025.05.005","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>The aim of this study was to report experience of treating patients who underwent implantation of a long term totally implantable venous access device (TIVAD) that was not flushed.</div></div><div><h3>Methods</h3><div>Patients who underwent TIVAD implantation between 1995 and 2016 were included in the present study. Sex, age, type of disease, indications, surgeon, device used, choice of venous access, type of procedure, morbidity, and follow up duration were considered.</div></div><div><h3>Results</h3><div>Five hundred and forty-four patients underwent surgical TIVAD implantation. The most common type of disease was solid tumours (508 patients, 93,4%). In 503 patients, the TIVAD was implanted in the cephalic vein. Seven (1.3%) patients were diagnosed with tumour recurrence by an oncologist (5/7 male, median age 57 years). Four (57.1%) patients had recurrent colorectal cancer, and three (42.9%) had recurrent breast cancer. For several months, these patients did not return to the hospital for port flushing. None of these devices were heparinised for 18–24 months; however, no signs of occlusion were detected.</div></div><div><h3>Conclusion</h3><div>This study shows that TIVAD can remain patent without flushing. Moreover, the lack of flushing could be economically advantageous and could provide relief for patients. Therefore, a larger study of this topic is needed.</div></div>","PeriodicalId":36502,"journal":{"name":"EJVES Vascular Forum","volume":"64 ","pages":"Pages 24-27"},"PeriodicalIF":1.4000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EJVES Vascular Forum","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666688X25000310","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction

The aim of this study was to report experience of treating patients who underwent implantation of a long term totally implantable venous access device (TIVAD) that was not flushed.

Methods

Patients who underwent TIVAD implantation between 1995 and 2016 were included in the present study. Sex, age, type of disease, indications, surgeon, device used, choice of venous access, type of procedure, morbidity, and follow up duration were considered.

Results

Five hundred and forty-four patients underwent surgical TIVAD implantation. The most common type of disease was solid tumours (508 patients, 93,4%). In 503 patients, the TIVAD was implanted in the cephalic vein. Seven (1.3%) patients were diagnosed with tumour recurrence by an oncologist (5/7 male, median age 57 years). Four (57.1%) patients had recurrent colorectal cancer, and three (42.9%) had recurrent breast cancer. For several months, these patients did not return to the hospital for port flushing. None of these devices were heparinised for 18–24 months; however, no signs of occlusion were detected.

Conclusion

This study shows that TIVAD can remain patent without flushing. Moreover, the lack of flushing could be economically advantageous and could provide relief for patients. Therefore, a larger study of this topic is needed.
不冲洗全植入式静脉通路装置的功能维持:临床病例报告
本研究的目的是报告治疗长期完全植入式静脉通路装置(TIVAD)植入术患者的经验。方法纳入1995年至2016年间接受TIVAD植入的患者。考虑性别、年龄、疾病类型、适应证、外科医生、使用的器械、静脉通路的选择、手术类型、发病率和随访时间。结果544例患者行手术植入TIVAD。最常见的疾病类型是实体瘤(508例,93.3%)。503例患者将TIVAD植入头静脉。7例(1.3%)患者被肿瘤科医生诊断为肿瘤复发(5/7男性,中位年龄57岁)。结直肠癌复发4例(57.1%),乳腺癌复发3例(42.9%)。几个月来,这些病人没有回到医院进行港口冲洗。这些装置在18-24个月内均未进行肝素化处理;然而,没有发现闭塞的迹象。结论本研究表明,TIVAD可以在不冲洗的情况下保持专利。此外,缺乏冲洗在经济上是有利的,可以为患者提供缓解。因此,需要对这一课题进行更大规模的研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
EJVES Vascular Forum
EJVES Vascular Forum Medicine-Surgery
CiteScore
1.50
自引率
0.00%
发文量
145
审稿时长
102 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信